|
|||||
|
|
Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs |
|
| Authors: | John E. Coughlin Seetharamaiyer Padmanabhan Guangrong Zhang Cassandra J. Kirk Chandrika P. Govardhan Brent E. Korba Kathleen O’Loughlin Carol E. Green Jon Mirsalis John D. Morrey Radhakrishnan P. Iyer |
| Affiliation: | 1. Spring Bank Pharmaceuticals Inc., Milford, MA, United States;2. Division of Virology and Molecular Biology, Georgetown University, Rockville, MD, United States;3. Biosciences Division, SRI International, Menlo Park, CA, United States;4. Institute for Antiviral Research, Utah State University, Logan, UT, United States |
| Abstract: | The acyloxyalkyl derivatives of a model anti-HBV dinucleotide were synthesized and evaluated as orally bioavailable prodrugs. Our studies have led to the identification of the first orally bioavailable dinucleotide prodrugs for further therapeutic development against the hepatitis B virus (HBV). |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ | |